Hematology (blood) Archives - Page 9 of 13

News
Reversal agents for direct-acting oral anticoagulants
September 20, 2019
DOACs are increasingly prescribed for anticoagulation, thanks to its multiple advantages.
News
NOACs benefit early stage chronic kidney disease patients
July 15, 2019
NOACs reduced risk of several adverse events compared with VKAs in a meta-analysis of chronic kidney disease patients.
News
No reduction in PE risk with vena cava filters after severe injury
July 9, 2019
MELBOURNE – “Given the cost and risks associated with a vena cava filter, our data suggest that there is no urgency to insert the filter in patients who can be treated with prophylactic anticoagulation within 7 days after injury,” the investigators wrote.
News
Rivaroxaban tied to higher GI bleeding than other NOACs
June 17, 2019
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.
News
CDC warns against misuse of opioid-prescribing guideline
April 24, 2019
Officials at the Centers for Disease Control and Prevention are advising against misapplication of the agency’s guideline on opioid prescribing.
News
Ticagrelor reversal agent looks promising
March 28, 2019
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.
News
Andexanet alfa effectively reverses factor Xa inhibition
March 18, 2019
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated with factor Xa inhibition.
News
Supplementary compression doesn’t improve DVT odds in critically ill
February 20, 2019
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
News
FDA aims to boost safety of platelets for transfusion
December 20, 2018
The agency is seeking input on ways to decrease the risk of bacterial contamination in platelets stored for 5 and 7 days after collection.
News
In-hospital blood saving strategy appears safe with anemia
December 18, 2018
Tolerating moderate in-hospital anemia did not negatively impact readmissions or mortality over 6 months.